Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
IMMvention Therapeutix General Information
IMMvention's orally dosed BACH1 inhibitors are currently in preclinical development. They have shown potential to increase fetal hemoglobin, which is believed to ameliorate sickle cell disease pathology[6][7].
Contact Information
Primary Industry
Biotech
Corporate Office
Durham, North Carolina
United States
United States
Drug Pipeline
TBL-100
Pre-clinicalKey Partnerships
Novo Nordisk A/S (strategic collaboration and license agreement announced January 22, 2025)
IMMvention Therapeutix Funding
No funding data available
To view IMMvention Therapeutix's complete valuation and funding history, request access »